Extended Data Fig. 1: Blood sample collection for ctDNA assessment.
From: Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma
Blood samples for ctDNA assessment were collected at pretreatment (T0), after each cycle of GP-NAC (T1–T3, 21 days after the prior cycle and before the next), and weekly during the adaptive phase (T4–T15) for patients with detectable ctDNA, continuing until clearance was confirmed in two consecutive tests). At the completion of CCRT, ctDNA assessment was conducted for all enrolled patients. DDP, cisplatin; RT, radiotherapy.
